Physician profile
Melissa Bennett
NPI 1306355300
$7,937.52
in general payments reported to CMS, 2019-2025
30 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,963 · 2022: $934 · 2023: $1,340 · 2024: $1,679 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,868 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,867.96 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,393.90 | 2021-2025 | Tremfya, Rybrevant |
| Abbvie INC. | $849.00 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $706.55 | 2021-2025 | Cabtreo, Jublia |
| Incyte Corporation | $677.44 | 2021-2025 | Opzelura |
| Genzyme Corporation | $580.03 | 2021-2025 | |
| Amgen INC. | $518.48 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $399.43 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $380.22 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $318.71 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $284.96 | 2023-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $282.30 | 2023-2025 | Zoryve |
| Pfizer INC. | $274.62 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $222.70 | 2021-2025 | |
| Dermavant Sciences, INC. | $141.06 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $127.57 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.91 | 2023-2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $98.85 | 2023-2024 | Ycanth |
| Galderma Laboratories, L.P. | $86.14 | 2021-2025 | Aklief |
| Ucb, INC. | $84.53 | 2022-2024 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Journey Medical Corporation | $51.24 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $49.82 | 2021-2023 | |
| Organon LLC | $49.14 | 2025 | |
| Stemline Therapeutics INC. | $44.75 | 2021 | |
| Almirall LLC | $35.27 | 2021-2025 | Klisyri |
| Merz North America, INC. | $33.94 | 2021 | |
| Cipher Pharmaceuticals US LLC | $24.21 | 2025 | Natroba, Spinosad |
| Medline Industries LP | $16.42 | 2024 | |
| Botanix Sb INC | $15.46 | 2025 | Sofdra |
| Abbott Laboratories | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.